These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30003238)

  • 1. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
    ; Guida F; Sun N; Bantis LE; Muller DC; Li P; Taguchi A; Dhillon D; Kundnani DL; Patel NJ; Yan Q; Byrnes G; Moons KGM; Tjønneland A; Panico S; Agnoli C; Vineis P; Palli D; Bueno-de-Mesquita B; Peeters PH; Agudo A; Huerta JM; Dorronsoro M; Barranco MR; Ardanaz E; Travis RC; Byrne KS; Boeing H; Steffen A; Kaaks R; Hüsing A; Trichopoulou A; Lagiou P; La Vecchia C; Severi G; Boutron-Ruault MC; Sandanger TM; Weiderpass E; Nøst TH; Tsilidis K; Riboli E; Grankvist K; Johansson M; Goodman GE; Feng Z; Brennan P; Johansson M; Hanash SM
    JAMA Oncol; 2018 Oct; 4(10):e182078. PubMed ID: 30003238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.
    Wikoff WR; Hanash S; DeFelice B; Miyamoto S; Barnett M; Zhao Y; Goodman G; Feng Z; Gandara D; Fiehn O; Taguchi A
    J Clin Oncol; 2015 Nov; 33(33):3880-6. PubMed ID: 26282655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro-surfactant protein B as a biomarker for lung cancer prediction.
    Sin DD; Tammemagi CM; Lam S; Barnett MJ; Duan X; Tam A; Auman H; Feng Z; Goodman GE; Hanash S; Taguchi A
    J Clin Oncol; 2013 Dec; 31(36):4536-43. PubMed ID: 24248694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People's Republic of China.
    Yang-Chun F; Min F; Di Z; Yan-Chun H
    Medicine (Baltimore); 2016 May; 95(18):e3568. PubMed ID: 27149479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
    Triphuridet N; Vidhyarkorn S; Worakitsitisatorn A; Sricharunrat T; Teerayathanakul N; Auewarakul C; Chungklay N; Krongthong W; Luengingkasoot S; Sornsamdang G; Patumanond J; Sritipsukho P
    Lung Cancer; 2018 Aug; 122():243-248. PubMed ID: 30032839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of circulating biomarkers for detection of lung cancer in a high-risk cohort.
    Borg M; Nederby L; Wen SWC; Hansen TF; Jakobsen A; Andersen RF; Weinreich UM; Hilberg O
    Cancer Biomark; 2023; 36(1):63-69. PubMed ID: 36404535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
    Sun N; Chen Z; Tan F; Zhang B; Yao R; Zhou C; Li J; Gao Y; Liu Z; Tan X; Zhou F; He MY; Shao K; Li N; Qiu B; Sun J; Yu Y; Wang S; Zhao Y; Shi X; He J
    Clin Cancer Res; 2013 Sep; 19(18):5136-45. PubMed ID: 24046070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
    Yang Q; Zhang P; Wu R; Lu K; Zhou H
    Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
    Fahrmann JF; Marsh T; Irajizad E; Patel N; Murage E; Vykoukal J; Dennison JB; Do KA; Ostrin E; Spitz MR; Lam S; Shete S; Meza R; Tammemägi MC; Feng Z; Hanash SM
    J Clin Oncol; 2022 Mar; 40(8):876-883. PubMed ID: 34995129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAULA's Test for Lung Cancer Screening.
    Clebak KT; Partin MT; Mendez-Miller M
    Am Fam Physician; 2020 Jul; 102(1):53-54. PubMed ID: 32603076
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel serum based biomarker panel has complementary ability to preclude presence of early lung cancer for low dose CT (LDCT).
    Wang X; Zhi X; Yang Z; Tian H; Li Y; Li M; Zhao W; Zhang C; Wang T; Liu J; Shen D; Zheng C; Zhao D; Yang S; Qi J; Xin H; Stojadinovic A; Avital I; Lee LJ; Rao J; Zhang W
    Oncotarget; 2017 Jul; 8(28):45345-45355. PubMed ID: 28514755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
    Front Immunol; 2020; 11():1173. PubMed ID: 32587591
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
    Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
    Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations.
    Debeljak Ž; Dundović S; Badovinac S; Mandić S; Samaržija M; Dmitrović B; Miloš M; Maričić L; Šerić V; Buljanović V
    Clin Chem Lab Med; 2018 Jul; 56(8):1328-1335. PubMed ID: 29648993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in the lung cancer diagnosis: a clinical perspective.
    Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
    Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer.
    Lee DS; Kim YS; Jung SL; Lee KY; Kang JH; Park S; Kim YK; Yoo IeR; Choi BO; Jang HS; Yoon SC
    Tumour Biol; 2012 Aug; 33(4):1065-73. PubMed ID: 22351560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Protein Biomarker Panel to Detect Non-Small-Cell Lung Cancer in Korea.
    Jung YJ; Katilius E; Ostroff RM; Kim Y; Seok M; Lee S; Jang S; Kim WS; Choi CM
    Clin Lung Cancer; 2017 Mar; 18(2):e99-e107. PubMed ID: 27836219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
    Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
    Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.